Novus And Verenium Introduce The Newest Addition To Novus's Enzyme Solutions Portfolio: CIBENZA® PHYTAVERSE™

 Novus And Verenium Introduce The Newest Addition To Novus's Enzyme Solutions
                       Portfolio: CIBENZA® PHYTAVERSE™

New enzyme technology unlocks the hidden value of phytate

PR Newswire

ST. LOUIS and SAN DIEGO, July 26, 2013

ST. LOUIS and SAN DIEGO, July 26, 2013 /PRNewswire/ -- Novus International,
Inc. and Verenium Corporation (Nasdaq: VRNM) today announced the name of their
new phytase enzyme product, CIBENZA^® PHYTAVERSE™. This new innovative
phytase is specifically designed to unlock more of the hidden nutritional
value in phytate for improved animal growth and well-being.


The two companies, which entered into a strategic partnership in 2011,
designed CIBENZA^® PHYTAVERSE™ to have specific performance characteristics
that offer significant advantages over current phytase products. These
performance characteristics include:

  oHigh in vivo activity under gastric conditions for sustained performance
  oImproved activity at low substrate concentrations to maximize phytate
  oHigh gastric stability for activity throughout the upper gastrointestinal
  oHigh intrinsic thermotolerance and pelleting stability
  oImproved bioavailability due to the elimination of the need for thermo
    protective coatings

"We're excited to bring this new enzyme solution to the market," said Gary
Hayen, Global Director Fermentation Products at Novus. "The partnership with
Verenium is allowing us to offer our customers the synergy of cutting-edge
enzyme technology and nutrition solutions knowledge which makes CIBENZA^®
PHYTAVERSE™ a valuable asset for today's feed industry."

Animal trial results have demonstrated the superior performance
characteristics that CIBENZA^® PHYTAVERSE™ provides, based on standard metrics
such as weight gain, feed conversion ratios and phosphorus mineralization
(tibia ash) versus other available phytase products. These results indicate
that inclusion of CIBENZA^® PHYTAVERSE™ in monogastric diets can provide
improved nutrition and economics to the animal feed industry.

"By combining Novus's animal nutrition expertise and extensive industry
knowledge with over 15 years of experience in developing high-performance
phytase products at Verenium, together we've been able to create a
next-generation phytase that exhibits superior performance characteristics
over those marketed today," said David Weiner, Vice President of R&D Strategy
and Partnerships at Verenium. "These important characteristics allow the
animal to more efficiently utilize the phosphorus and other nutrients
necessary for improved animal health and nutrition, and can provide producers
an increased return on investment."

Novus and Verenium expect to launch this product in certain geographical
regions beginning in 2013.

About Novus International, Inc.
Novus International, Inc. is headquartered in metropolitan St. Louis,
Missouri, U.S.A. and serves customers in nearly 100 countries around the
world. A global leader in developing animal health and nutrition solutions,
Novus's products include ALIMET^® and MHA^® feed supplements, ACTIVATE^®
nutritional feed acid, ACIDOMIX^® preservative premixture, ADVENT^®
coccidiosis control, CIBENZA^® feed additive, MINTREX^® chelated trace
mineral, SANTOQUIN^® feed preservative, MERA™MET aquaculture feed additive,
AGRADO^® feed antioxidant and many other specialty ingredients. Stratum®
Nutrition, a division of Novus Nutrition Brands, LLC, focuses on human
nutrition through specialty and functional ingredients for manufacturers of
foods, beverages and dietary supplements ( Novus is
privately owned by Mitsui & Co. (U.S.A.), Inc. and Nippon Soda Co., Ltd. For
more information visit ®Novus, ALIMET, MHA, ACTIVATE,
International, Inc. and are registered in the United States and other
countries. ^®ADVENT is a trademark of Viridus Animal Health, LLC, and is
registered in the United States and other countries. ^®STRATUM NUTRITION is a
trademark of Novus Nutrition Brands, LLC, and is registered in the United
States and other countries. ^®PREVIDA is a registered trademark of TIN, Inc.
International, Inc.© 2013 Novus International, Inc. All rights reserved.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in
developing high-performance enzymes. Verenium's tailored enzymes are
environmentally friendly, making products and processes greener and more
cost-effective for industries, including the global food and fuel markets.

Forward-Looking Statements For Verenium
Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include, but are not limited to, statements related to Verenium's technology,
products and product candidates (including, in each case, their value,
potential for revenue growth and expected near-term and longer term revenue),
product pipeline (including the timing for commercial launch of any product
candidates), capabilities and commercialization activities. Such statements
are only predictions, and actual events or results may differ materially from
those projected in such forward-looking statements. Factors that could cause
or contribute to the differences include, but are not limited to, risks
associated with Verenium's strategic focus, technologies, products and product
candidates and product pipeline (including Verenium's ability to identify,
develop and commercialize new products and product candidates, either
independently or with collaborators or partners, and market demand for those
products and product candidates), dependence on patents and proprietary
rights, protection and enforcement of its patents and proprietary rights, the
commercial prospects of the industries in which Verenium operates and sells
products, Verenium's dependence on manufacturing and/or license agreements,
its ability to achieve milestones under existing and future collaboration
agreements, the ability of Verenium and its partners to commercialize its
technologies and products (including by obtaining any required regulatory
approvals) using Verenium's technologies, the timing for launching any
commercial products and projects, the ability of Verenium and its
collaborators to market and sell any products that it or they commercialize,
the development or availability of competitive products or technologies, the
future ability of Verenium to enter into and/or maintain collaboration and
joint venture or partnership agreements and licenses on a timely basis or at
all, and risks and other uncertainties more fully described in Verenium's
filings with the Securities and Exchange Commission, including, but not
limited to, Verenium's annual report on Form 10-K for the year ended December
31, 2012 and any updates contained in its subsequently filed quarterly reports
on Form 10-Q. These forward-looking statements speak only as of the date
hereof, and Verenium expressly disclaims any intent or obligation to update
these forward-looking statements.

Novus Contacts:
Tracy Barfield

Barbara Hansen

Verenium Contact:
Sarah Carmody
Sr. Manager, Corporate Communications

SOURCE Verenium Corporation

Press spacebar to pause and continue. Press esc to stop.